Company intelligence / Profile preview

Element Biosciences

San Diego, California, United Stateselementbiosciences.com ↗

Ownership: Private
Employees: ~350
Development stage: Commercial

Overview

Element Biosciences has launched the AVITI and AVITI24 platforms for high-quality benchtop DNA sequencing and multiomic analyses. The systems are being adopted globally by academic labs, biotech companies, cancer researchers, and others. Their technologies enable direct in-sample sequencing of DNA/RNA/proteins/cell morphology without library prep. Over 160 commercial orders have been received as of early 2024. No clinical trial results apply as this is a research tools/platforms company.

Modalities: DeviceMultiomics technology
Industry: Non-Drug Biotech

Partnerships

Twist Bioscience (co-developing end-to-end NGS solutions)Jumpcode Genomics (integration/validation of CRISPRclean® technology with AVITI system)

Beyond the preview

Go deeper on Element Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Element Biosciences.

Explore the full profile